Man Group
VRTX icon

Man Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Man Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,200
Closed -$218K – 2124
2021
Q3 		$218K Buy
+1,200
New +$234K ﹤0.01% 1742

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Man Group's VRTX Position: Q2 2026 in Review

Man Group reduced its Vertex Pharmaceuticals (VRTX) stake by 41% in Q2 2026, selling an estimated $43.2M and leaving 139,233 shares worth $69.2M. The position accounts for 0.11% of the portfolio, ranked #203.

Man Group first reported a position in VRTX in Q1 2018 and has held it in 31 quarters since. The position peaked at $221M in Q1 2024. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Man Group held 139,233 shares of Vertex Pharmaceuticals worth $69.2M as of Q2 2026.
  • Man Group sold 97,565 Vertex Pharmaceuticals shares in Q2 2026, an estimated $43.2M.
  • Vertex Pharmaceuticals made up 0.11% of Man Group's portfolio in Q2 2026, its #203 holding.
  • Man Group first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 31 quarters since.
  • Man Group's Vertex Pharmaceuticals position peaked at $221M in Q1 2024.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.